Chardan reiterates Buy on Ocular Therapeutix, $23 target
Chardan Capital maintained a Buy rating on Ocular Therapeutix and set a $23.00 price target, implying 125.7% upside versus the Sep 15 close of $10.19.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.